Premium
Antiinflammatory Constituents from Eclipta prostrata using RAW264.7 Macrophage Cells
Author(s) -
Tewtrakul Supinya,
Subhadhirasakul Sanan,
Tansakul Pimpimon,
Cheenpracha Sarot,
Karalai Chatchanok
Publication year - 2011
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.3383
Subject(s) - ic50 , nitric oxide , lipopolysaccharide , tumor necrosis factor alpha , prostaglandin e2 , macrophage , pharmacology , chemistry , traditional medicine , nitric oxide synthase , pharmacognosy , prostaglandin , in vitro , biochemistry , biology , immunology , biological activity , medicine , endocrinology , organic chemistry
The whole plant extract of Eclipta prostrata and its isolated compounds were tested for their antiinflammatory effects against lipopolysaccharide (LPS)‐induced nitric oxide (NO), prostaglandin E 2 (PGE 2 ) and tumor necrosis factor‐alpha (TNF‐α) release in RAW264.7 cells, as well as for the antiinflammatory mechanism of the active compound on mRNA expression. Among the isolated compounds, orobol (5) exhibited the highest activity against NO release with an IC 50 value of 4.6 μ m , followed by compounds 1, 2 and 4 with IC 50 values of 12.7, 14.9 and 19.1 μ m , respectively. The IC 50 value of compound 5 against PGE 2 release was found to be 49.6 μ m , whereas it was inactive towards TNF‐α (IC 50 > 100 μ m ). The mechanism of orobol (5) was found to down‐regulate iNOS and COX‐2 mRNA expression in a concentration‐dependent manner. The present study may support the traditional use of Eclipta prostrata for the treatment of inflammatory‐related diseases. Copyright © 2011 John Wiley & Sons, Ltd.